Wuxi Apptec announced in its mid-2024 report that the company achieved revenue of RMB 1,724.09 million, a YoY decrease of 8.6%; and a net profit attributable to shareholders of RMB 423.98 million, a YoY decrease of 20.2%. The company provides integrated, end-to-end new drug R&D and production services to the global pharmaceutical and life sciences industry, and has operational bases in Asia, Europe, North America, and other regions. In the first half of 2024, the company added more than 500 new customers, and global demand for the company's services continues to grow. As of the end of June 2024, the company has orders on hand totaling RMB 43.1 billion, excluding the COVID-19 commercialization project, which represents a YoY growth of 33.2%. During the reporting period, the company continued to invest in capacity and scale construction, and is expected to achieve revenue of RMB 38.3-40.5 billion in 2024, with positive growth after excluding the COVID-19 commercialization project.

Wuxi Apptec announced in its mid-2024 report that the company achieved revenue of RMB 1,724.09 million, a YoY decrease of 8.6%; and a net profit attributable to shareholders of RMB 423.98 million, a YoY decrease of 20.2%. The company provides integrated, end-to-end new drug R&D and production services to the global pharmaceutical and life sciences industry, and has operational bases in Asia, Europe, North America, and other regions. In the first half of 2024, the company added more than 500 new customers, and global demand for the company's services continues to grow. As of the end of June 2024, the company has orders on hand totaling RMB 43.1 billion, excluding the COVID-19 commercialization project, which represents a YoY growth of 33.2%. During the reporting period, the company continued to invest in capacity and scale construction, and is expected to achieve revenue of RMB 38.3-40.5 billion in 2024, with positive growth after excluding the COVID-19 commercialization project.